全球雄激素性脱发市场规模、份额和趋势分析报告 – 行业概况和 2031 年预测

雄激素性脱发市场分析

全球雄激素性脱发市场正在经历大幅增长，这得益于人们对脱发治疗认识的提高以及女性和男性雄激素性脱发患病率的上升。包括使用米诺地尔和非那雄胺在内的治疗方案的进步，以及低强度激光治疗和毛发移植等创新疗法，正在扩大市场格局。此外，向个性化医疗的转变正在促进根据个体患者资料开发个性化治疗方案。各种临床试验证明，研发投入的增加也在推动市场扩张。此外，随着可支配收入的增加和技术的进步，人们在家庭护理环境中寻求有效的脱发解决方案的趋势日益增长，预计将提高这些治疗的可及性。因此，雄激素性脱发市场有望实现显着增长，为行业中的老牌参与者和新进入者提供大量机会，以利用这个不断扩大的寻求有效头发修复解决方案的消费者群体。

雄激素性脱发市场规模

2023 年全球雄激素性脱发市场规模价值 14.3 亿美元，预计到 2031 年将达到 29.8 亿美元，2024 年至 2031 年预测期内的复合年增长率为 9.60%。除了对市场价值、增长率、细分、地理覆盖范围和主要参与者等市场情景的见解外，Data Bridge Market Research 策划的市场报告还包括深度专家分析、患者流行病学、管道分析、定价分析和监管框架。

雄激素性脱发市场趋势

“个性化治疗方法的采用日益增多”

The androgenetic alopecia market is witnessing a notable trend toward the increasing adoption of personalized treatment approaches that cater to individual patient needs. As awareness of the condition grows, patients are seeking tailored therapies that align with their specific genetic profiles and treatment preferences. For instance, advancements in pharmacogenomics are enabling healthcare providers to offer customized solutions based on genetic testing, which can determine the most effective treatment regimen for hair loss. Additionally, the rise of telemedicine is facilitating consultations that allow patients to receive personalized recommendations without the need for in-person visits. Companies such as Hairmax are leveraging these trends by providing tailored laser therapy devices that can be used conveniently at home. This shift towards personalized solutions enhances patient satisfaction and compliance and drives market growth by attracting a broader consumer base that values individualized care in addressing androgenetic alopecia.

Report Scope and Androgenetic Alopecia Market Segmentation       

Androgenetic Alopecia Market Definition

Androgenetic alopecia, commonly known as male or female pattern baldness, is a hereditary condition characterized by progressive hair thinning and loss. It results from a combination of genetic predisposition and hormonal influences, particularly the effects of androgens (male hormones) on hair follicles. In men, this condition typically manifests as a receding hairline and balding at the crown, while women generally experience diffuse thinning across the scalp, often retaining their frontal hairline. The condition can begin as early as puberty and may lead to significant psychological distress due to its impact on self-image.

Androgenetic Alopecia Market Dynamics

Drivers

• Increasing Prevalence of Hair Loss

The increasing prevalence of hair loss, particularly androgenetic alopecia, is a significant market driver, with studies indicating that approximately fifty percent of men and a substantial number of women experience some degree of hair thinning by the age of 50. Factors contributing to this rise include genetic predisposition, hormonal fluctuations, and lifestyle elements such as stress and poor nutrition. For instance, research has shown that androgens, particularly dihydrotestosterone (DHT), play a crucial role in hair follicle miniaturization, leading to progressive hair loss. Additionally, a report from the American Academy of Dermatology noted that androgenetic alopecia affects around 25% of men in their twenties and nearly 75% by age of 70. This growing incidence is creating a larger consumer base actively seeking effective treatment options, which drives demand for various therapies, including topical solutions such as minoxidil and surgical interventions such as hair transplants. As more individuals seek solutions to combat hair loss, the market for androgenetic alopecia treatments is expected to expand significantly.

• Increasing Aging Population

The aging population significantly drives the demand for effective treatments for androgenetic alopecia, as the incidence of hair loss increases with age. According to the World Health Organization, by 2050, the number of individuals aged 60 and older is expected to reach 2 billion, representing approximately 21% of the global population. Research indicates that nearly 75% of men and about 50% of women will experience some degree of hair thinning by the age of 70. This demographic shift creates a larger consumer base actively seeking hair loss treatments to maintain their appearance and self-esteem. As older adults become more aware of available therapeutic options ranging from pharmaceutical treatments such as minoxidil and finasteride to surgical interventions such as hair transplants the market for androgenetic alopecia solutions is anticipated to expand, catering to the growing demand for effective and accessible treatments tailored to this demographic.

Opportunities

• Increasing Technological Advancements in Treatment Solutions

Technological advancements in treatment solutions for androgenetic alopecia represent a significant market opportunity, enhancing both the effectiveness and accessibility of therapies. Innovations such as new pharmacological solutions, including FDA-approved medications such as finasteride and minoxidil, have improved patient outcomes by promoting hair regrowth and slowing hair loss. Moreover, advanced laser therapy devices, such as low-level laser therapy (LLLT) systems, have gained popularity due to their non-invasive nature and proven efficacy in stimulating hair follicles. For instance, devices such as the iRestore Laser Hair Growth System are gaining traction among consumers for their ease of use at home. Additionally, minimally invasive hair transplant techniques, such as the Follicular Unit Extraction (FUE) method, have revolutionized surgical options, allowing for more precise and natural-looking results with reduced recovery time. These advancements meet the increasing demand for effective hair restoration solutions and cater to a broader audience, including those who may have previously considered traditional methods too invasive or costly. As technology continues to evolve, it opens new avenues for growth and innovation within the androgenetic alopecia market.

• Growing Awareness and Acceptance of Hair Loss Conditions

Growing awareness and acceptance of hair loss conditions and their treatment solutions present a significant market opportunity for the androgenetic alopecia sector. Recent studies indicate that over 60% of individuals experiencing hair loss actively seek information about treatment options, reflecting a notable shift in societal attitudes towards hair restoration therapies. This change is facilitated by increased visibility in mainstream media, where celebrities and influencers openly discuss their hair loss journeys and the various treatments they have pursued. For instance, platforms such as Instagram and TikTok feature hashtags such as #HairRestoration, which attract millions of views and foster communities that encourage seeking solutions for hair loss. Additionally, educational campaigns by dermatologists and hair restoration clinics have played a crucial role in informing the public about effective treatments, such as topical solutions such as minoxidil and surgical options such as hair transplants. As more individuals recognize the benefits of addressing hair loss, the demand for effective androgenetic alopecia cure continues to rise, creating a robust market opportunity for companies specializing in androgenetic alopecia solutions.

Restraints/Challenges

• Affordability and Cost Barriers

Affordability and cost barriers present significant challenges to the global androgenetic alopecia market, limiting access to effective treatments for many individuals, particularly in low-income regions. Advanced solutions such as hair transplants can cost several thousand dollars, making them prohibitive for a large segment of the population. For instance, the average cost of a hair transplant in the U.S. ranges several thousand dollars, depending on the procedure's complexity and the number of grafts required. This financial burden can deter patients from seeking necessary treatment and may also discourage healthcare providers from investing in the latest technologies and solutions. Additionally, prescription medications such as finasteride and minoxidil, while effective, can also impose ongoing costs that not everyone can afford, particularly when health insurance plans do not cover these treatments. Consequently, the high costs associated with androgenetic alopecia treatments restrict patient access, creating a barrier to market growth and limiting the potential for broader adoption of innovative solutions in addressing hair loss.

• Complex Regulatory Frameworks

Regulatory hurdles pose significant challenges for the global androgenetic alopecia market, as stringent requirements and lengthy approval processes can delay the introduction of innovative therapies. Companies developing new treatments must navigate complex regulatory frameworks set by agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), which require extensive clinical trials to demonstrate safety and efficacy. For instance, the approval process for a new hair restoration drug can take several years, during which companies must invest substantial resources into research, development, and compliance with regulatory standards. This can be particularly daunting for smaller companies or start-ups that lack the financial backing to endure prolonged timelines without generating revenue. Consequently, delays in obtaining necessary approvals can hinder market entry for potentially ground-breaking therapies, limiting patient access to the latest solutions for androgenetic alopecia. The combination of regulatory scrutiny and the need for comprehensive clinical data can slow down innovation, ultimately affecting the availability of effective treatments for those suffering from hair loss.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Androgenetic Alopecia Market Scope

The market is segmented on the basis of treatment, gender, route of administration, end users, and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

• Minoxidil
• Finasteride
• Dutasteride
• Oral Antiandrogens
• Hair Transplant
• Low-Level Laser Therapy
• Counseling
• Others

Gender

• Male
• Female

Route of Administration

• Oral
• Topical

End-Users

• Clinics
• Hospitals
• Diagnostic Centers
• Surgical Centers
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

Androgenetic Alopecia Market Regional Analysis

The market is analysed and market size insights and trends are provided by country, treatment, gender, route of administration, end users, and distribution channel as referenced above.

市场报告涉及的国家包括北美洲的美国、加拿大和墨西哥、欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、亚太地区（APAC）的中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区（APAC）的其他地区、沙特阿拉伯、阿联酋、南非、埃及、以色列、中东和非洲（MEA）的其他地区、南美洲的巴西、阿根廷和南美洲其他地区。

北美是雄激素性脱发市场的领军者，这得益于行业巨头的存在以及人口中脱发的日益普遍。该地区的高可支配收入使消费者能够投资于先进的治疗方法，而这些治疗方法通常价​​格不菲。此外，支持研发的强大医疗基础设施也促进了创新治疗方案的开发。因此，北美继续成为脱发治疗最新进展的中心，进一步巩固了其主导市场地位。

预计 2024 年至 2031 年，亚太地区的雄激素性脱发市场将大幅增长。这一增长主要是由于呼吸系统疾病（包括慢性呼吸系统疾病和其他功能障碍）发病率的上升，这增加了对有效呼吸护理解决方案的需求。此外，医疗保健基础设施的不断改善，尤其是该地区新兴经济体的基础设施改善，促进了人们更多地获得先进的医疗技术。这些因素加上医疗保健投资的增加，使亚太地区成为预测期内的关键增长区域。

报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的大量或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。  

雄激素性脱发市场份额

市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对市场的关注有关。

在雄激素性脱发市场中运营的市场领导者是：

• Vitabiotics Ltd.（英国）
• 太阳制药工业有限公司 (印度)
• 默克公司（美国）
• Dr. Reddy's Laboratories Ltd.（印度）
• 西普拉（印度）
• 强生服务公司（美国）
• Laboratoire Native（法国）
• Aurobindo Pharma（印度）
• Hairmax International, LLC（美国）
• iRESTORE 头发生长系统（美国）
• Curallux, LLC（美国）
• Apira Science（美国）
• Theradome Inc.（美国）
• Lifes2good（美国）

雄激素性脱发市场的最新发展

• 2023 年 12 月，Sun Pharmaceutical Industries Ltd. 与 Aclaris 建立战略合作伙伴关系，授予 Sun Pharma 使用 JAK 抑制剂 deuruxolitinib 和芦可替尼的其他同位素变体治疗斑秃和雄激素性脱发的独家权利
• 2023 年 7 月，Cosmo Pharmaceuticals 启动了其外用雄激素受体阻断药物 Clascoterone Solution 的 3 期临床试验
• 2023 年 6 月，雷迪博士实验室有限公司宣布扩大其在印度的仿制药部门，推出 RgenX，这是一个专门的部门，为患者提供更广泛的平价产品
• 2023 年 6 月，辉瑞公司获得美国 FDA 批准 Litfulo（ritlecitinib），这是一种治疗脱发相关脱发的药物，其作用是阻断导致脱发增加的炎症信号
• 2023 年 3 月，Sun Pharmaceutical Industries Ltd. 完成对 Concert Pharmaceuticals, Inc. 的收购，该公司专注于开发针对各种脱发形式的创新治疗方案

SKU-63691